Elicio Therapeutics, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Elicio Therapeutics, Inc. (ELTX) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $8.27 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-08-13
- Elicio Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2026-03-31 was $8.13, a 8.86% decline year-over-year.
- Elicio Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2025-03-31 was $8.92, a 98.22% increase year-over-year.
- Elicio Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2024-03-31 was $4.50.
- Elicio Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2022-03-31 was $1.93, a 87.89% decline year-over-year.
- Elicio Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $7.63, a 112.53% increase from fiscal 2024.
- Elicio Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $3.59, a 62.91% decline from fiscal 2023.
- Elicio Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $9.68, a 401.55% increase from fiscal 2022.
- Elicio Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $1.93, a 87.50% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $8.27 10-Q · filed 2026-08-13 | |||
| 2026-03-31 | $8.13 10-Q · filed 2026-05-11 | |||
| 2025-12-31 | $7.63 10-K · filed 2026-03-12 | |||
| 2025-09-30 | $7.40 10-Q · filed 2025-11-13 | |||
| 2025-06-30 | $7.36 10-Q · filed 2025-08-07 | |||
| 2025-03-31 | $8.92 10-Q · filed 2025-05-13 | |||
| 2024-12-31 | $3.59 10-K · filed 2025-03-31 | |||
| 2024-09-30 | $5.67 10-Q · filed 2024-11-13 | |||
| 2024-06-30 | $4.57 10-Q · filed 2024-08-13 | |||
| 2024-03-31 | $4.50 10-Q · filed 2024-05-15 | |||
| 2023-12-31 | $9.68 10-K · filed 2024-03-29 | |||
| 2023-09-30 | $9.96 10-Q · filed 2023-11-13 | |||
| 2023-06-30 | $10.00 10-Q · filed 2023-08-14 | |||
| 2022-12-31 | $1.93 10-K · filed 2023-03-17 | |||
| 2022-09-30 | $1.93 10-Q · filed 2022-11-14 | |||
| 2022-06-30 | $1.93 10-Q · filed 2022-08-15 | |||
| 2022-03-31 | $1.93 10-Q · filed 2022-05-16 | |||
| 2021-12-31 | $15.44 10-K · filed 2022-03-30 | |||
| 2021-09-30 | $15.60 10-Q · filed 2021-11-12 | |||
| 2021-06-30 | $15.89 10-Q · filed 2021-08-12 | |||
| 2021-03-31 | $15.94 10-Q · filed 2021-05-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |